Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/1/2000 First Published: 6/1/1999


1.		Phase II/III Randomized Study of SCH 54031 (Polyethylene Glycol Interferon alfa-2b) Versus Interferon alfa-2b in Patients With Newly Diagnosed Chronic Phase Myelogenous Leukemia (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70				Pharmaceutical / Industry				SPRI-C98-026 SPRI-C98-026-054, SPRI-I98-026


2.		High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831AM1)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				P04831 NCT00457418

Last Modified: 2/15/2007 First Published: 5/28/2004


3.		Phase I/II Randomized Study of PEG-Interferon alfa-2b in Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				Any age				NCI				MDA-ID-02115 NCT00085384

Last Modified: 7/31/2008 First Published: 9/1/2002


4.		Phase II Study of PEG-Interferon alfa-2b in Patients With Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-01143 NCI-G-02-2102, NCT00045279

Last Modified: 4/12/2008 First Published: 2/21/2003


5.		Phase II Randomized Study of Bevacizumab and PEG-Interferon alfa-2b in Patients With Metastatic or Unresectable Carcinoid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MDA-ID-02063 NCI-4772, NCT00055809, 4772

Last Modified: 7/31/2007 First Published: 8/24/2004


6.		Phase II Study of PEG-Interferon alfa-2b, Sargramostim (GM-CSF), and Thalidomide in Patients With Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				MUSC-100614 CELGENE-MUSC-100614, MUSC-HR-10423, NCT00090870

Last Modified: 1/16/2006 First Published: 9/9/2005


7.		Phase II Study of Pegylated-Interferon alfa-2b and Rituximab in Patients With Advanced Indolent Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-02033A

Last Modified: 7/19/2007 First Published: 1/6/2006


8.		Phase II Randomized Study of Neoadjuvant PEG-Interferon alfa-2b in Patients With Resectable Stage II-IV Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MDA-ID-01450 NCT00276523

Last Modified: 8/23/2006 First Published: 10/7/2005


9.		Phase II Study of PEG-Interferon alfa-2b and Thalidomide in Patients With Recurrent or Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				WSU-C-2257 WSU-HIC-120900M01-FB, NCT00238329


10.		Study of PEG-Intron for Plexiform Neurofibromas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 months to 21 years				NCI, Other				UPCI 06-116 NCT00396019

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute